Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Pearl Huang, incoming CEO of Dunad Therapeutics, is betting that covalent drugs can push the boundaries of the small-molecule modality to supercharge targeted protein degradation.
Pearl Huang learned how important it is to choose the right drug modality for a target on the first project of her biopharma career. When she joined Merck & Co. as a biochemist in 1990, she was tasked with unravelling how the human papillomavirus (HPV) causes cervical cancer — with an eye to small-molecule interventions. Despite rapid results, management shut the programme down to focus on a HPV vaccine. The savvy reprioritization decision made way for the worldwide rollout of Gardasil, and left a strong mark on Huang. “I realized that I was going to have to be intellectually flexible, to be willing to work on lots of things,” she says.